Close

Roth Capital Comments on Regeneron (REGN) Following Q2 Results; Affirms 'Buy' Rating

August 5, 2014 12:29 PM EDT Send to a Friend
Roth Capital affirms Regeneron Pharmaceuticals (Nasdaq: REGN) at Buy with a target price of $399 following Q2 results.Analyst Joseph Pantginis ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login